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Abstract
The clearance is a pharmacokinetic measurement of the renal excretion representing the plasma volume 
completely cleared by the substance, in a certain amount of time (Rowland and Tozer, 2011); it is usually 
measured in l/h for drugs. The total clearance of the body represents the sum of the metabolic clearance and the 
renal clearance (Hauschke et al., 2007). As the half time (t ½) shortens, the drug will be eliminated faster and the 
absorption period will be shorter (Cristina and Chirciu, 2010).
The purpose of this study was to evaluate the renal clearance of two products based on pyrantel (the tested 
product and the reference product). The measurements were carried out with regard to the half time and the 
maximum plasmatic concentration of the drugs.
A number of 12 cats were included in the study; clinically healthy of European breed. According to the testing 
protocol, the cats were administered pyrantel in a concentration of 230 mg, in two stages, following a randomized 
list. Before and after administration, 11 blood samples were collected, at different intervals of time, for three 
consecutive days. The main parameters determined were: renal clearance, half-time of the drug and the maximum 
concentration in blood.
It was observed, that for the same concentration of pyrantel pamoate (230 mg), the clearance was different 
for the two groups: for the ϐirst group, the clearance was 0.84 ± 0.44 mg/h, respectively 0.58 ± 0.38 mg/h for the 
second group. The half time was 1.58 ± 0.68 hours for the ϐirst group while for the second group, it was 2.38 ± 1.05 
hours. These values were recorded when the maximum concentration was recorded (1.5 ± 0.85 hours for group 
1 and 2.29 ± 2.09 hours for group two). The comparative analysis of the levels from the analyzed data revealed 
differences given mainly by individual ϐluctuations, which were situated within the bioequivalence standards.
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INTRODUCTION
Bioavailability represents the percentage 
of a administered pharmacological product that 
enters the blood stream, after administration. For 
the same active substance, its bioavailability may 
vary according to the species and subject. The oral 
bioavailability it is inϐluenced by the size, lipophilic 
character, the electrical charge and the bonding 
to food particles of every tablet (Criveanu, 2008; 
Cristina and Chirciu, 2010).
The maximum concentration (C
max
) displays 
the maximum value reached in the blood, after 
administering the drug (Tracy, 2004).  C
max 
also shows 
the rate and extent of absorption, linked especially 
with the clearance of the subjects’ body. For example, 
a drug with a poor absorption and a moderate rate 
of elimination will not accumulate in the body, 
presenting a weak pharmacodynamic effect. 
The half time (T1/2) reveals the necessary 
time for the plasmatic concentration of the drug, 
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to decrease by 50%. T
1/2 
is important to determine 
the necessary time for the concentration of the 
active substance to reach a plateau concentration. 
At the same time, T1/2 reveals the moment when 
the active substance will be eliminated from the 
body after administration, allowing the adjustment 
of the doses in the case that there are necessary 
multiple dosages (Trepanier, 2013). 
The clearance is a name used speciϐically in 
pharmacokinetics and it refers to the volume of 
plasma completely cleaned of the active substance, 
in an amount of time (Rowland and Tozer, 2011). 
The clearance reϐlects all routes of elimination 
of the drug, including biotransformation, biliary 
excretion, glomerular ϐiltration and tubular 
secretion (Hauschke et al., 2007, Ritter et al., 
2008). The shorter the half-life of the drug, the 
more rapidly it will be eliminated from the body 
and maximum period of absorption will be shorter 
(Cristina and Chirciu, 2010).
The evaluation of the results obtained in the 
following study, started from the premise that 
bioequivalence of two products is achieved when, 
between the tested product and the reference one 
are only small differences regarding their systemic 
bioavailability (Ognean, 2008). 
MATERIALS AND METHODS 
The research was conducted in the faculty of 
Veterinary Medicine, Cluj-Napoca, in the Depart-
ment of Physiology, during a period of three 
months (March – May 2013).
In this study, 12 clinically healthy cats were 
included, European breed, coming from both rural 
and urban areas. The animals were selected using 
rigorous inclusion/exclusion criteria. During the 
period of the study, the animals were housed and 
fed according to the protocol. Administering the 
tablets was done according to a randomization list.
The active substance, pyrantel, was given for 
both the tested product and the reference in a 
concentration of 230 mg. This way, it was easier 
to analyze the pharmacokinetics of its molecules. 
The bioequivalence testing was performed in two 
phases, separated by a washout period of 14 days.
Eleven blood samples were collected, for three 
consecutive days, at different time periods (Tab.1).
The cats’ health status was evaluated during the 
study, according to the protocol from table 2; for this 
purpose, clinical, hematological and biochemical 
test were carried out. All the subjects who did not 
correspond in terms of hematological, biochemical 
or clinical results were eliminated from the study.
Tab. 1. Exact hours at which the blood samples 
were collected
Day 1 (0.0) and 0.5,  1.0, 1.5, 2, 4, 8, 12,
Day 2 24.0, 36.0
Day 3 48.0
Tab. 2. The examination protocol
Procedure Screening Phase I
Wash-
out
7-14 
days
Phase II
Final 
exami-
nation
Study day -7…-1 0 1 2 3 0 1 2 3 ….+7
Volunteer information and written consent 
Verifi cation of inclusion/exclusion criteria  l l
Physical examination l l
Vital signs l l l l
Clinical chemistry l l
Hematology l l
Urinalysis l l
Serology l
Product administration l l
Blood collection for drug concentrations 
measurement
l l l l l l
Adverse Events observing and recording l l l l l
The Comparative Evaluation of The Renal Clearance for two Products Based on Pyrantel
492
 Bulletin UASVM Veterinary Medicine 71(2) / 2014
In order to determine the bioequivalence 
parameters, the Kinetica 5.0 software was used. 
For this study, only the following parameters were 
of interest: Clearance; Peak concentration (C
max
); 
Half-life (T
1/2
)
The statistical interpretation of the data 
obtained was carried using ANOVA by means of 
the Tukey-Kramer Multiple comparisons test. The 
statistical analysis was carried out using GraphPad 
software version 3.05; the charts were generated 
using the OriginPro 8.5 software.
RESULTS AND DISSCUSSION
The chemical analysis of the tested formulas 
showed that regarding the praziquantel, the active 
substance was administered in equal amounts for 
both the reference and tested product (230 mg). 
Regarding the maximum concentration of 
the active substance, the average results were 
116.24±55.15 ng/mL for the tested product and 
148.91±96.81 ng/mL for the reference product 
(Fig. 1).
Also, in the case of the reference drug adminis-
tered, there was a maximum recorded value of 362.69 
ng/mL, compared to the maximum value recorded in 
the case of the tested product – 210.1 ng/mL.
The mean values obtained for the half-time 
(T
1/2
)
 
of the two products, were close at range, 
with a mean of 1.58 ± 0.68 h for the tested product 
and 2.38 ± 1.05 h for the reference drug (Fig. 2).
Fig 1. Individual variations of C
max  
for the tested product 
(goup T) and for the reference (group R) 
Fig. 2. Fluctuations recorded for the tested drug and 
for the reference, regarding the half-life of pyrantel
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For the tested product there was registered 
a minimum value of 1.12 h and a maximum value 
of 3.56 h. Comparatively, the maximum value 
obtained for the reference product was of 4.42 h.
For the clearance there were higher values 
obtained in the case of the tested product, with a 
mean of 0.84 ± 0.44 mg*h/(ng/mL), compared to 
the reference product, were a mean value of 0.58 ± 
0.38 mg*h/(ng/mL) was recorded (ϐig. 3). For the 
tested product, a maximum value for the clearance 
of 1.7 mg*h/(ng/mL) was recorded, compared to 
1.28 mg*h/(ng/mL), the maximum value obtained 
for the reference product. 
Pyrantel pamoate is an anthelmintic drug, 
with a low systemic availability. Its peak serum 
concentrations occur 1–3 hours after a administra-
tion (McEvoy, 2009). It is partially metabolized in 
the liver and approximately 50% of an oral dose 
is excreted through feces and only a small portion 
through the kidneys (Maddison, 2008).
Although the concentration of the active subs-
tance was the same for the tested and reference 
products, the determined parameters showed indi-
vidual variations, without any statistical signiϐi-
cance, the two products being bioequivalent.
Cmax. Regarding the peak concentration of the 
active substance, it was observed that there were 
high ϐluctuations of the recorded results for the 
tested product compared to the reference one, 
although the same amount of pyrantel pamoate 
was administered for both (ϐig.1). Thus it can be 
observed that the active substance, pyrantel, from 
the reference drug, was absorbed to a larger extent 
compared to the tested product.                                                              
However, analyzing the individual results for 
the tested product, there were smaller variations 
compared to the reference product, showing a 
more stable absorption for the tested product. 
Small ϐluctuations were recorded for the individual 
results, compared to the mean results for both 
products.
Both the maximum and minimum values 
recor ded for the tested product were higher than 
the minimum and maximum results recorded for 
the reference product. Similar studies performed 
on dogs (Morovján et al., 1998; Ognean et al., 
2008), demonstrated that the substance, pyrantel 
pamoate, has a good absorption in the body.
T1/2. Regarding the half-life (T1/2) of 
pyrantel pamoate, there were variations between 
the tested product and the reference, with a higher 
variability for the reference product (Fig. 2).
Similar to the maximum concentration, also 
for the half-life of the product, the individual 
values recorded for the tested product varied non-
signiϐicant from the mean results.
For the tested product there was recorded a 
minimum value of 1.12 h and a maximum value 
of 3.56 h. Comparatively, the maximum value 
obtained for the reference product was 4.42 h. The 
half-life of the product along with the clearance, 
show how well the active substance is being 
eliminated from the body.  
Clearance. The results obtained for the clea-
rance of the pyrantel showed a ϐluctuating trend 
both for the reference drug and also for the tested 
product (Fig. 3). 
Fig. 3. Clearance for the tested drug and for the reference
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Correlated with the half-life of the substance, 
it can be observed that the tested product is being 
eliminated slower from the body, although its half 
time is faster compared to the half time
 
of the 
reference product.
A similar study regarding the pharmacody-
namics of pyrantel was performed on horses, 
proving that pyrantel pamoate is eliminated 
mainly by feces (Gokbulut et al., 2001).
Another study carried out on pigs, compared 
the pharmacokinetics of oral pyrantel versus 
the intravenously administered pyrantel. It was 
observed that the intravenously administered 
pyrantel it is distributed faster in the body, 
reaching its peak concentration sooner that 
the oral product. Nevertheless, its short time of 
persistence in the organism indicates that that the 
oral product has an increased efϐiciency on a long-
term (Bjorn, 1996).
CONCLUSIONS
Administering an equal quantity of pyrantel, 
both for the tested product and for the reference 
drug (230 mg), similar evolutions have been 
recorded for the investigated parameters (Cmax, 
Tmax and clearance). Analyzing the individual 
results obtained, it was observed a variating trend 
both for the tested and reference product. 
Regarding the peak concentration, pyrantel 
was absorbed in a higher quantity in from the 
reference product, compared to the tested drug. 
This is a positive aspect due to the fact that there 
is a greater quantity of active substance available 
in the bloodstream, not being necessary to 
supplement the doses.
The half-time of pyrantel was longer for the 
reference product, compared to the tested product. 
This aspect, linked to its bigger absorption, makes 
its anti-parasitic action more efϐicient.
With regard to the clearance, this was faster 
for the reference product, thus the residues won’t 
last for long in the body.
The individual results recorded for the tested 
product had smaller variability regarding pyrantel 
pamoate, this way being much more stable in 
regard to its pharmacokinetics.
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